JPWO2019241734A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019241734A5
JPWO2019241734A5 JP2020569831A JP2020569831A JPWO2019241734A5 JP WO2019241734 A5 JPWO2019241734 A5 JP WO2019241734A5 JP 2020569831 A JP2020569831 A JP 2020569831A JP 2020569831 A JP2020569831 A JP 2020569831A JP WO2019241734 A5 JPWO2019241734 A5 JP WO2019241734A5
Authority
JP
Japan
Prior art keywords
seq
composition
sequence
staufen1
modulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020569831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527649A5 (https=
JP2021527649A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/037355 external-priority patent/WO2019241734A1/en
Publication of JP2021527649A publication Critical patent/JP2021527649A/ja
Publication of JP2021527649A5 publication Critical patent/JP2021527649A5/ja
Publication of JPWO2019241734A5 publication Critical patent/JPWO2019241734A5/ja
Priority to JP2024088206A priority Critical patent/JP2024123017A/ja
Pending legal-status Critical Current

Links

JP2020569831A 2018-06-14 2019-06-14 Ｓｔａｕｆｅｎ１調節剤および関連する方法 Pending JP2021527649A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024088206A JP2024123017A (ja) 2018-06-14 2024-05-30 Ｓｔａｕｆｅｎ１調節剤および関連する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862685269P 2018-06-14 2018-06-14
US62/685,269 2018-06-14
PCT/US2019/037355 WO2019241734A1 (en) 2018-06-14 2019-06-14 Staufen1 regulating agents and associated methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024088206A Division JP2024123017A (ja) 2018-06-14 2024-05-30 Ｓｔａｕｆｅｎ１調節剤および関連する方法

Publications (3)

Publication Number Publication Date
JP2021527649A JP2021527649A (ja) 2021-10-14
JP2021527649A5 JP2021527649A5 (https=) 2022-06-14
JPWO2019241734A5 true JPWO2019241734A5 (https=) 2022-06-14

Family

ID=68842359

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020569831A Pending JP2021527649A (ja) 2018-06-14 2019-06-14 Ｓｔａｕｆｅｎ１調節剤および関連する方法
JP2024088206A Pending JP2024123017A (ja) 2018-06-14 2024-05-30 Ｓｔａｕｆｅｎ１調節剤および関連する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024088206A Pending JP2024123017A (ja) 2018-06-14 2024-05-30 Ｓｔａｕｆｅｎ１調節剤および関連する方法

Country Status (4)

Country Link
US (2) US11946046B2 (https=)
EP (1) EP3807291A4 (https=)
JP (2) JP2021527649A (https=)
WO (1) WO2019241734A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4615973A1 (en) * 2022-11-08 2025-09-17 University of Utah Research Foundation Staufen-1 modulating agents, compositions, and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241845A1 (en) * 1998-05-22 2004-12-02 Luc Desgroseillers Mammalian staufen and use thereof
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
WO2006039399A2 (en) 2004-09-29 2006-04-13 University Of Rochester Staufen 1 (stau1) - mediated mrna decay
WO2009143371A2 (en) * 2008-05-21 2009-11-26 Intradigm Corporation COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF
US9206479B2 (en) * 2011-02-09 2015-12-08 University Of Rochester Methods and compositions related to Staufen 1 binding sites formed by duplexing Alu elements
EP2753695A1 (en) 2011-09-07 2014-07-16 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Strategies for prevention and/or treatment of diseases based on cd40 silencing
EP3274456B1 (en) * 2015-03-25 2020-06-24 Università Degli Studi Di Trento Rna interference mediated therapy for neurodegenerative diseases
EP3551641A4 (en) 2016-12-08 2021-01-13 University of Utah Research Foundation STAUFEN1 ACTIVE SUBSTANCES AND RELATED PROCEDURES
TW201920672A (zh) * 2017-08-08 2019-06-01 新加坡商波濤生命科學有限公司 寡核苷酸組合物及其使用方法

Similar Documents

Publication Publication Date Title
US11873490B2 (en) Antisense oligomers for treatment of conditions and diseases
JP2024045199A5 (https=)
CN102171342B (zh) 杜兴肌营养不良中有效的外显子(44)跳跃方法及相关手段
US20230250429A1 (en) Opa1 antisense oligomers for treatment of conditions and diseases
US20240084309A1 (en) Compositions and methods for inhibiting plp1 expression
TW202106877A (zh) 調節剪接及轉譯之方法及組合物
JP7660515B2 (ja) 病態及び疾患の治療用アンチセンスオリゴマー
WO2012027558A2 (en) OPTIMIZED miRNA CONSTRUCTS
TW202405172A (zh) 用於減少富白胺酸重複激酶2 (lrrk2)之表現的寡核苷酸及其用於預防及/或治療人類疾病的用途
US20250186508A1 (en) Par2 modulation to alter myelination
KR20240165951A (ko) 녹내장 치료 방법
CN119365598A (zh) 用于治疗单基因神经发育障碍的组合物和方法
US20240294907A1 (en) Selective delivery of oligonucleotides to glial cells
JP2021527649A5 (https=)
JPWO2019241734A5 (https=)
US20230374519A1 (en) Compounds and methods for modulating pmp22
US20220372488A1 (en) Compositions and methods for treating neurodegenerative disorders
WO2020185651A2 (en) Compositions and methods for treating huntington's disease
WO2023060092A1 (en) Compositions and methods for treatment of prion diseases
TW202242113A (zh) 用於治療與多囊蛋白表現相關之病況及疾病之組合物
US20250283086A1 (en) Compositions and methods for treatment of kidney disease
Gulam et al. Antisense therapy and its application in biopharmaceutical research: past, present and future
WO2025063185A1 (ja) １本鎖ポリヌクレオチド
Ahammad et al. Peptide-Mediated Delivery of α-Synuclein Targeting ASO: Pharmacokinetics, Safety, and CNS Efficacy in a Synucleinopathy Model
EP4728075A2 (en) Compositions and methods for modulating apoe